129724-43-2

Usage

Uses

Used in Pharmaceutical Industry:
2',4'-Dihydroxy-3',6'-dimethoxychalcone is used as a potential therapeutic agent for its antioxidant, anti-inflammatory, and anti-cancer effects. Its presence in certain plant species suggests a role in the plant's defense mechanisms, and research has indicated its potential in treating various diseases, making it a valuable subject for further investigation and development in the pharmaceutical field.
Used in Antioxidant Applications:
2',4'-Dihydroxy-3',6'-dimethoxychalcone is utilized as an antioxidant, which can help protect cells from damage caused by reactive oxygen species. Its antioxidant properties make it a candidate for the development of treatments aimed at combating oxidative stress-related conditions.
Used in Anti-inflammatory Applications:
2',4'-Dihydroxy-3',6'-dimethoxychalcone is employed as an anti-inflammatory agent, potentially mitigating inflammation and related symptoms in various diseases. Its anti-inflammatory effects can be beneficial in the management of conditions characterized by chronic inflammation.
Used in Anti-cancer Applications:
2',4'-Dihydroxy-3',6'-dimethoxychalcone is used as an anti-cancer agent, with research suggesting its potential in the treatment of various types of cancer. Its ability to target and inhibit cancer cell growth and proliferation makes it a promising candidate for further exploration in oncology.

Upstream product

• 13326-72-2 3,5-bis(benzyloxy)-4-methoxybenzaldehyde 
• 27229-56-7 [3,5-bis(benzyloxy)-4-methoxyphenyl]methanol 
• 13326-69-7 methyl 3,5-bis(benzyloxy)-4-methoxybenzoate 
• 24093-81-0 methyl 3,5-dihydroxy-4-methoxybenzoate 
• 99-24-1 methyl galloate 
• 6274-74-4 2,6-dibenzyloxy-1,4-dimethoxybenzene 
• 20032-42-2 2,5-dimethoxyresorcinol 
• 102-92-1 Cinnamoyl chloride 
• 102-92-1 cinnamoyl chloride 
• 42528-81-4 2,6-bis-benzyloxy-benzene-1,4-diol 
• 6625-45-2 2,6-bis-benzyloxy-[1,4]benzoquinone 
• 55020-64-9 1,2,3-tris-benzyloxybenzene 
• 87-66-1 2-hydroxyresorcinol 

Downstream Products

• 1969289-10-8 (-)-celosine 
• 1969289-10-8 (+)-celosine 
• 3316-54-9 7-hydroxy-5,8-dimethoxyflavone 
• 632-85-9 wogonin 

Relevant academic research and scientific papers

Isolation, structure elucidation, and KDD study of (-)-Celosine, a new skeleton with potent anti-atherosclerosis activity

Natural (-)-Celosine was isolated as a novel endocyclicditerpene with an unprecedented skeleton from Celosia cristata L. Its structure was established by comprehensive 1D and 2D NMR spectroscopic analysis in combination with single-crystal X-ray crystallographic diffraction of synthesized (+)-Celosine. (-)-Celosine was expected to have an anti-atherosclerotic activity in vivo, and myeloperoxidase (MPO) expression may be the mechanism underlying this anti-atherosclerotic activity.

Synthesis, evaluation and quantitative structure–activity relationship (QSAR) analysis of Wogonin derivatives as cytotoxic agents

A novel series of 49 wogonin derivatives were synthesized by introducing group at 7-, 8- or B ring of wogonin. The cytotoxic activities against HepG2, A549 and BCG-823 cancer cell lines were also investigated in vitro. Several of them showed obvious cytotoxic activities and compound 3h possessed the highest potency against HepG2, A549, and BCG-823 with IC50 values of 1.07 μM, 1.74 μM and 0.98 μM, respectively. A quantitative structure-activity relationship (QSAR) study of these synthetic derivatives as well as wogonin indicated that high solubility and low octanol/water partition coefficient are favorable, and excessive electrostatic properties and refractivity are unfavorable for the cytotoxic activities of these wogonin derivatives. These findings and results provide a base for further investigations.

Chalcone derivative, preparing method, pharmaceutical composition and application

The invention relates to a chalcone derivative, a preparing method, a pharmaceutical composition and application, provides a compound with the general formula I, and pharmaceutically-acceptable salt or solvate or polymorphic substances or metabolites or prodrugs of the compound, and further provides a preparing method of the compound of the structure shown in the general formula I, a pharmaceutical composition including the substance, and application of the substance in preparing medicine for treating or preventing inflammation. The general formula I is shown in the description, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are H, substituted or unsubstituted C1-C4 alkyl, hydroxyl, alkoxy, amino, halogen, C1-C4 substituted acylamino and C1-C4 acyl; R11 and R12 are substituted or unsubstituted C1-C4 alkyl.